Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

89 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2016.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 26,097,588 shares of 104,661,494 outstanding shares and own 24.94% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), JPMORGAN CHASE & CO (3,430,158 shares), FRANKLIN RESOURCES INC (3,280,584 shares), WELLINGTON MANAGEMENT GROUP LLP (2,149,678 shares), Arrowpoint Asset Management, LLC (2,018,729 shares), Bank of New York Mellon Corp (1,941,730 shares), BlackRock Fund Advisors (1,398,009 shares), Polar Capital LLP (1,296,371 shares), VANGUARD GROUP INC (825,652 shares), and CANADA PENSION PLAN INVESTMENT BOARD (582,900 shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.